Fortress Biotech, Inc. (FBIO)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Fortress Biotech, Inc. (FBIO)
Company Performance

Current Price

as of Oct 16, 2024

$1.75

P/E Ratio

N/A

Market Cap

$48.24M

Description

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Metrics

Overview

  • HQBay Harbor Islands, FL
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerFBIO
  • Price$1.75+1.74%

Trading Information

  • Market Cap$48.24M
  • Float79.42%
  • Average Daily Volume (1m)935,498
  • Average Daily Volume (3m)499,157
  • EPS-$16.62

Company

  • Revenue$82.62M
  • Rev Growth (1yr)-14.32%
  • Net Income-$10.95M
  • Gross Margin53.40%
  • EBITDA Margin-151.54%
  • EBITDA-$22.57M
  • EV$11.07M
  • EV/Revenue0.13
  • P/EN/A
  • P/S0.39
  • P/B2.21
Documents
SEC Filings
8-K (2024-09-23)
8-K (2024-08-13)
8-K (2024-07-25)
8-K (2024-07-19)
8-K (2024-07-05)
8-K (2024-06-28)
8-K (2024-06-25)
8-K (2024-05-29)
8-K (2024-05-15)
8-K (2024-03-28)
8-K (2024-01-26)
8-K (2024-01-03)
8-K (2023-11-14)
8-K (2023-10-26)
8-K (2023-10-10)
8-K (2023-08-14)
8-K (2023-06-23)
8-K (2023-06-16)
8-K (2023-05-15)
8-K (2023-05-05)
8-K (2023-04-13)
8-K (2023-03-30)
8-K (2023-02-09)
10-Q (2024-08-13)
10-Q (2024-05-15)
10-Q (2023-11-14)
10-Q (2023-08-14)
10-Q (2023-05-15)
10-K (2024-03-28)
10-K (2023-03-31)
Earnings Calls
Earnings Report 2022Q3
Earnings Report (2022-11-10)
Factset
Factset Business Description
Factset Street Account
Insider transaction: Fortress Biotech CEO & Chairman Lindsay Rosenwald discloses purchase of 1.6M shares - Form 4 ($1.43, 0.00) (2023-11-16T22:53:31Z)
Fortress Biotech reports Q3 GAAP EPS ($0.94) vs FactSet ($3.21) [5 est, ($3.75)-(2.40)] ($1.34, 0.00) (2023-11-14T21:14:00Z)
Fortress Biotech prices ~5.9M unit offering at $1.70 per unit through Roth Capital Partners ($2.08, 0.00) (2023-11-10T13:17:47Z)
Fortress Biotech partner Cyprium Therapeautics receives notice of Sentynl's election to effect the Approval Deadline Transfer related to CUTX-101 agreement - 8-K ($1.80, 0.00) (2023-10-26T21:03:28Z)
Fortress Biotech commences offering of units of indeterminate amount through Roth Capital Partners on a reasonable best-efforts basis ($2.08, 0.00) (2023-11-09T22:07:03Z)
Fortress Biotech announces 1-for-15 reverse stock split ($0.33, 0.00) (2023-10-09T16:51:24Z)